$CDNA
CareDx Inc

2023 Q3 Form 10-Q Financial Statement

#000121723423000180 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $67.19M $70.30M
YoY Change -15.33% -12.81%
Cost Of Revenue $24.53M $25.89M
YoY Change -13.32% -6.0%
Gross Profit $42.66M $44.41M
YoY Change -16.45% -16.35%
Gross Profit Margin 63.49% 63.18%
Selling, General & Admin $52.44M $50.96M
YoY Change 13.78% -2.35%
% of Gross Profit 122.93% 114.73%
Research & Development $19.00M $20.23M
YoY Change -14.82% -10.6%
% of Gross Profit 44.54% 45.56%
Depreciation & Amortization $3.670M $3.666M
YoY Change 21.28% 33.6%
% of Gross Profit 8.6% 8.25%
Operating Expenses $95.98M $97.93M
YoY Change -0.75% -4.33%
Operating Profit -$28.78M -$27.62M
YoY Change 66.0% 27.19%
Interest Expense $3.171M $2.871M
YoY Change 158.86% 500.63%
% of Operating Profit
Other Income/Expense, Net $5.218M $2.603M
YoY Change 682.31% -9740.74%
Pretax Income -$23.57M -$25.02M
YoY Change 41.34% 15.06%
Income Tax -$80.00K -$68.00K
% Of Pretax Income
Net Earnings -$23.49M -$24.95M
YoY Change 38.64% 15.01%
Net Earnings / Revenue -34.95% -35.49%
Basic Earnings Per Share -$0.43 -$0.46
Diluted Earnings Per Share -$0.43 -$0.46
COMMON SHARES
Basic Shares Outstanding 54.17M shares 53.79M shares
Diluted Shares Outstanding 54.18M shares 53.85M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.8M $286.0M
YoY Change -7.41% -7.33%
Cash & Equivalents $75.98M $87.79M
Short-Term Investments $195.8M $198.2M
Other Short-Term Assets $7.300M $7.676M
YoY Change -12.78% -11.33%
Inventory $17.98M $18.84M
Prepaid Expenses
Receivables $51.69M $51.63M
Other Receivables $0.00 $0.00
Total Short-Term Assets $345.2M $360.8M
YoY Change -11.08% -10.66%
LONG-TERM ASSETS
Property, Plant & Equipment $35.36M $36.08M
YoY Change 3.84% 9.66%
Goodwill $40.20M $39.70M
YoY Change 7.2% 7.01%
Intangibles $46.46M $43.53M
YoY Change 5.93% -6.02%
Long-Term Investments
YoY Change
Other Assets $2.441M $2.036M
YoY Change -50.04% -59.74%
Total Long-Term Assets $156.0M $154.0M
YoY Change -0.22% 12.08%
TOTAL ASSETS
Total Short-Term Assets $345.2M $360.8M
Total Long-Term Assets $156.0M $154.0M
Total Assets $501.2M $514.8M
YoY Change -7.96% -4.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.972M $9.880M
YoY Change -15.56% -41.51%
Accrued Expenses $38.00M $39.10M
YoY Change 8.33% 9.03%
Deferred Revenue $5.766M $6.058M
YoY Change 17.31% 41.05%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $72.67M $74.50M
YoY Change 3.39% -5.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $245.0K $247.0K
YoY Change -2.39% -1.98%
Total Long-Term Liabilities $245.0K $247.0K
YoY Change -2.39% -1.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.67M $74.50M
Total Long-Term Liabilities $245.0K $247.0K
Total Liabilities $107.0M $109.6M
YoY Change -0.73% 12.14%
SHAREHOLDERS EQUITY
Retained Earnings -$534.2M -$509.9M
YoY Change 21.0% 20.12%
Common Stock $937.0M $923.6M
YoY Change 5.64% 5.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $394.1M $405.2M
YoY Change
Total Liabilities & Shareholders Equity $501.2M $514.8M
YoY Change -7.96% -4.89%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$23.49M -$24.95M
YoY Change 38.64% 15.01%
Depreciation, Depletion And Amortization $3.670M $3.666M
YoY Change 21.28% 33.6%
Cash From Operating Activities -$10.18M -$499.0K
YoY Change 43.81% -87.13%
INVESTING ACTIVITIES
Capital Expenditures $2.520M $2.362M
YoY Change -143.11% -135.53%
Acquisitions
YoY Change
Other Investing Activities $1.020M $17.71M
YoY Change -101.46% 138.1%
Cash From Investing Activities -$1.500M $15.35M
YoY Change -98.02% 1842.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -30.00K -1.566M
YoY Change -97.09% -21.58%
NET CHANGE
Cash From Operating Activities -10.18M -499.0K
Cash From Investing Activities -1.500M 15.35M
Cash From Financing Activities -30.00K -1.566M
Net Change In Cash -11.71M 13.28M
YoY Change -86.03% -361.27%
FREE CASH FLOW
Cash From Operating Activities -$10.18M -$499.0K
Capital Expenditures $2.520M $2.362M
Free Cash Flow -$12.70M -$2.861M
YoY Change 930.01% -203.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
us-gaap Defined Benefit Plan Type Extensible List
DefinedBenefitPlanTypeExtensibleList
http://fasb.org/us-gaap/2023#PostemploymentRetirementBenefitsMember
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
465876000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
999000 usd
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1482000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
58000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1598000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10563000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-420000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19648000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
457544000 usd
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-3211000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
79000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
413000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12513000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2092000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-21697000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
443549000 usd
us-gaap Profit Loss
ProfitLoss
-48702000 usd
us-gaap Profit Loss
ProfitLoss
-41345000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
26454000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23227000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7093000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5363000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1000000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2652000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1822000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-852000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-486000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
488000 usd
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
564000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
2091000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-540000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-75000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15225000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10562000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-12000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2506000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
514000 usd
cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2677000 usd
cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1962000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4486000 usd
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-12290000 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 usd
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
158000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
172000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25345000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4562000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
102000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2100000 usd
CY2018Q1 cdna Number Of Renal Transplant Patients
NumberOfRenalTransplantPatients
1700 patient
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-509900000 usd
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
282700000 usd
CY2022Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
50000000 usd
CY2022Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P2Y
CY2023Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
12000 shares
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
100000 usd
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
800000 usd
CY2023Q2 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
48600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023 and 2022, approximately 44% and 54%, respectively, of total revenue was derived from Medicare. For the six months ended June 30, 2023 and 2022, approximately 43% and 54%, respectively, of total revenue was derived from Medicare.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, approximately 33% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either June 30, 2023 or December 31, 2022.</span></div>
CY2023Q2 cdna Unsubmitted Reimbursement Claims For Medicare
UnsubmittedReimbursementClaimsForMedicare
3200 unique_solution
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24953000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24953000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21697000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21697000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-48702000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48702000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41345000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41345000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53846260 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53846260 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53745299 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53745299 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53133149 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53133149 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8573690 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8573690 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5093000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5093000 shares
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3475000 usd
cdna Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants
22000 usd
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5152000 usd
CY2023Q1 us-gaap Increase Decrease In Equity Securities Fv Ni
IncreaseDecreaseInEquitySecuritiesFvNi
-1000000 usd
CY2022 cdna Business Combination Contingent Consideration Liability Measurement Input Discount Rate
BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate
0.12
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87786000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
166832000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
584000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
204000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88370000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
167036000 usd
CY2023Q2 cdna Marketable Securities Amortized Cost Short Term
MarketableSecuritiesAmortizedCostShortTerm
194887000 usd
CY2023Q2 cdna Marketable Securities Accumulated Unrecognized Holding Gain Loss Short Term
MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm
2026000 usd
CY2023Q2 cdna Marketable Securities Fair Value Short Term
MarketableSecuritiesFairValueShortTerm
196913000 usd
CY2023Q2 cdna Marketable Securities Amortized Cost Long Term
MarketableSecuritiesAmortizedCostLongTerm
5100000 usd
CY2023Q2 cdna Marketable Securities Accumulated Unrecognized Holding Gain Loss Long Term
MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm
-3775000 usd
CY2023Q2 cdna Marketable Securities Fair Value Long Term
MarketableSecuritiesFairValueLongTerm
1325000 usd
CY2023Q2 cdna Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
199987000 usd
CY2023Q2 cdna Marketable Securities Accumulated Unrecognized Gain Loss
MarketableSecuritiesAccumulatedUnrecognizedGainLoss
-1749000 usd
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
198238000 usd
CY2022Q4 cdna Marketable Securities Amortized Cost Short Term
MarketableSecuritiesAmortizedCostShortTerm
203168000 usd
CY2022Q4 cdna Marketable Securities Accumulated Unrecognized Holding Gain Loss Short Term
MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm
232000 usd
CY2022Q4 cdna Marketable Securities Fair Value Short Term
MarketableSecuritiesFairValueShortTerm
203400000 usd
CY2022Q4 cdna Marketable Securities Amortized Cost Long Term
MarketableSecuritiesAmortizedCostLongTerm
5000000 usd
CY2022Q4 cdna Marketable Securities Accumulated Unrecognized Holding Gain Loss Long Term
MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm
-2924000 usd
CY2022Q4 cdna Marketable Securities Fair Value Long Term
MarketableSecuritiesFairValueLongTerm
2076000 usd
CY2022Q4 cdna Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
208168000 usd
CY2022Q4 cdna Marketable Securities Accumulated Unrecognized Gain Loss
MarketableSecuritiesAccumulatedUnrecognizedGainLoss
-2692000 usd
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
205476000 usd
CY2023Q2 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
194887000 usd
CY2022Q4 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
203168000 usd
CY2023Q2 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
0 usd
CY2022Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
0 usd
CY2023Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
194887000 usd
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
203168000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
39700000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
37500000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
77864000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30370000 usd
CY2023Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
5215000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42279000 usd
CY2023Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
79114000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30370000 usd
CY2023Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
5215000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
43529000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
73764000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
27175000 usd
CY2022Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
4788000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41801000 usd
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
75014000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
27175000 usd
CY2022Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
4788000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
43051000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1606000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1545000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3196000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3168000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3198000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
6150000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
5981000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
5085000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5072000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
16793000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42279000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3661000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2962000 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5494000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
4306000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9685000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11964000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
18840000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
19232000 usd
CY2023Q2 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
13797000 usd
CY2022Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
14816000 usd
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10858000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6115000 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6058000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5342000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5809000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5591000 usd
CY2023Q2 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
2650000 usd
CY2022Q4 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
2062000 usd
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4633000 usd
CY2023Q2 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
2084000 usd
CY2022Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
2189000 usd
CY2023Q2 cdna Accrued License And Other Collaboration Fees
AccruedLicenseAndOtherCollaborationFees
1000000 usd
CY2022Q4 cdna Accrued License And Other Collaboration Fees
AccruedLicenseAndOtherCollaborationFees
1000000 usd
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
928000 usd
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1025000 usd
CY2023Q2 cdna Accrued Capital Expenditures
AccruedCapitalExpenditures
420000 usd
CY2022Q4 cdna Accrued Capital Expenditures
AccruedCapitalExpenditures
1316000 usd
CY2023Q2 cdna Accrued Shipping Expenses
AccruedShippingExpenses
329000 usd
CY2022Q4 cdna Accrued Shipping Expenses
AccruedShippingExpenses
489000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3862000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4553000 usd
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
50175000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
49131000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32100000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5800000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30600000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1972000 usd
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1372000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
3955000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
2785000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
1972000 usd
CY2022Q2 us-gaap Lease Cost
LeaseCost
1372000 usd
us-gaap Lease Cost
LeaseCost
3955000 usd
us-gaap Lease Cost
LeaseCost
2785000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M2D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M3D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.071
CY2022Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
500000 usd
CY2022Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-500000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3821000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7960000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7709000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7019000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7166000 usd
CY2023Q2 cdna Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
10604000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
44279000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7881000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
36398000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5809000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30589000 usd
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1366000 usd
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
952000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
2699000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1924000 usd
CY2014Q2 cdna Number Of Milestone Payments
NumberOfMilestonePayments
6 milestone_payment
CY2022Q4 us-gaap Malpractice Insurance Maximum Coverage Per Incident
MalpracticeInsuranceMaximumCoveragePerIncident
15000000 usd
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 usd
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1200000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1200000 usd
CY2023Q2 cdna Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
3000 shares
cdna Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
3000 shares
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4000 usd
CY2023Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4000 usd
CY2022Q2 cdna Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
cdna Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1490462 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2921925 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2141330 shares
cdna Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services
ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices
11296 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3302174 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
680788 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
680788 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.60
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3750 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.98
cdna Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
233356 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
491831 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
118886 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
118886 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
32.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
96416 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
96416 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
33.70
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
578023 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3383661 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.57
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
19000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
31000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1300000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-61000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-68000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
56000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70301000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80634000 usd
CY2023Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
1757 shares
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
24.34
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y9M7D
CY2023Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
854000 usd
CY2023Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
1323 shares
CY2023Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
26.16
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y11M8D
CY2023Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3080 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
854000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12400000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12700000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12593000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26454000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23227000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-68000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
56000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
147563000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
160050000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36084000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
35529000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
800000 usd
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
cdna-20230630_lab.xml Edgar Link unprocessable
0001217234-23-000180-index-headers.html Edgar Link pending
0001217234-23-000180-index.html Edgar Link pending
0001217234-23-000180.txt Edgar Link pending
0001217234-23-000180-xbrl.zip Edgar Link pending
cdna-20230630.htm Edgar Link pending
cdna-20230630.xsd Edgar Link pending
cdna-20230630x10qxexx311.htm Edgar Link pending
cdna-20230630x10qxexx312.htm Edgar Link pending
cdna-20230630x10qxexx321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
cdna-20230630_cal.xml Edgar Link unprocessable
cdna-20230630_def.xml Edgar Link unprocessable
cdna-20230630_pre.xml Edgar Link unprocessable
cdna-20230630_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending